News and Reports
-
ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART
7 March 2017Download -
Vascular Dynamics? Announces Expedited Access Pathway Designation by FDA for MobiusHD® to Accelerate US Access for Treatment of Resistant Hypertension
1 February 2017Download -
DePuy Synthes Acquires Interventional Spine Expandable Cage Technology to Accelerate Growth in Spine
3 January 2017Download -
ARMO BioSciences? Immunotherapy AM0010 Receives Orphan Drug and Fast Track Designations from the U.S. FDA for the Treatment of Pancreatic Cancer
14 November 2016Download -
Celldex Expands Antibody and Immuno-Oncology Portfolio with the Acquisition of Kolltan Pharmaceuticals
1 November 2016Download -
Curetis Announces Positive Top Line Data from U.S. FDA Trial
25 October 2016Download -
Gynesonics completes enrollment in SONATA FDA trial for treatment of uterine fibroids
18 October 2016Download -
ObsEva starts Phase IIb EDELWEISS study in endometriosis
11 October 2016Download -
Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares
5 October 2016Download -
Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016
31 August 2016Download -
Paratek Initiates Phase 3 Study of Oral-Only Omadacycline in ABSSSI
15 August 2016Download -
ObsEva initiates Phase 1 for OBE022 in Preterm Labor
28 July 2016Download -
Cell Medica Acquires Delenex Therapeutics
12 July 2016Download -
ObsEva Receives FDA Clearance to Initiate Phase 2b Study of OBE2109 in Endometriosis
6 July 2016Download -
AnaptysBio Initiates Multiple Ascending Dose Cohorts in ANB020 Phase 1 Clinical Trial
6 July 2016Download -
Advanced Accelerator Applications Announces FDA Priority Review for Lutathera
27 June 2016Download -
Paratek Announces that Omadacycline Met All Primary and Secondary Efficacy Outcomes Designated by FDA and EMA in a Phase 3 Study in Acute Bacterial Skin Infections
16 June 2016Download -
Eiger BioPharmaceuticals Closes Merger With Celladon Renamed Eiger and New Trading Symbol (NASD: EIGR, as of March 23) Developing a Clinical Stage Pipeline of Orphan Disease Programs
22 March 2016Download -
Skyepharma to merge with Vectura Group
16 March 2016Download -
ARMO BioSciences Raises $50 Million Series C Financing
10 February 2016Download -
Kolltan Pharmaceuticals Provides Update on Clinical Pipeline, Corporate Developments and Near-Term Milestones
8 January 2016Download -
NUVASIVE to aquire Ellipse Technologies
6 January 2016Download -
Vascular Dynamics’ MobiusHD™ System Receives CE Mark for the Treatment of Resistant Hypertension
6 January 2016Download -
Allena Pharmaceuticals Raises $53 Million in Series C Financing
9 December 2015Download -
HBM co-leads CHF 60 million Series B financing of ObsEva
23 November 2015Download